20170406 Telix Logo.png
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
October 04, 2021 17:34 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed...
20170406 Telix Logo.png
Telix Establishes Commercial Hub in Geneva, Switzerland
October 04, 2021 03:17 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and GENEVA, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has established a new commercial...
20170406 Telix Logo.png
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
September 20, 2021 20:31 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today welcomed the Society of Nuclear Medicine and...
20170406 Telix Logo.png
NCCN Guidelines Updated to Include PSMA-PET Imaging
September 13, 2021 20:36 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today welcomed the updated National Comprehensive Cancer...
20170406 Telix Logo.png
FDA Approves Phase II Kidney Cancer Therapy Study
September 13, 2021 18:41 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug...
20170406 Telix Logo.png
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
September 12, 2021 18:36 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and BOLOGNA, Italy, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
Telix In-Licences Novel Tumour Microenvironment PET Tracer
September 09, 2021 01:34 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
Michael Didocha Joins Telix as Chief Financial Officer, Americas
August 31, 2021 07:12 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that Michael Didocha has joined the...
20170406 Telix Logo.png
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
August 18, 2021 18:47 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program...
20170406 Telix Logo.png
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
August 17, 2021 21:26 ET | Telix Pharmaceuticals Limited
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...